Connect with us

Hi, what are you looking for?

Jewish Business News


The UK court overturned Teva’s Copaxone patent

The UK court ruled in favor of Mylan and its Dutch partner Synthon and canceled all of Teva’s patents on Copaxone 40 mg in the country



The British Supreme Court ruled Thursday in favor of Mylan and its Dutch partner Synthon, and canceled all Teva’s Copaxone for 40 mg in the country based on obviousness.

A statement by Mylan believes that the victory in court is yet another milestone for the company to bring high quality generic versions to the MS community around the world.

“This victory is yet another important milestone for Mylan, and this U.K. court decision only further increases Mylan’s confidence in its ability to bring high quality, lower-cost generic versions of Copaxone to the multiple sclerosis community and patients around the world,” Mylan stated.

Over the past eight years, Mylan has managed to overcome four patents litigation protecting Teva’s flagship drug in the U.S. eight Citizen Petitions, injunction proceedings in India, more than 15 regulatory challenges, patent litigations or commercial actions across Europe, and now the litigation in the U.K., in addition to obtaining dismissal of Teva’s suit against the FDA seeking to delay approval of the 20 mg/mL product.

Teva will publish its financial statements for the third quarter on November 2, when analysts predict revenues of $5.63 billion, with a profit of $1.05 per share.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


Now Platika joins and elite club of $10 billion plus Israeli firms.